Fig. 5

Disease-modifying and supportive treatments for MPS VI infographic. This infographic provides a summary of key information found in the MPS VI treatment guidelines. For further details, please see the original paper published in the Orphanet Journal of Rare Diseases [7]. The overall Appraisal of Guidelines for Research and Evaluation (AGREE II) assessment score for the original guideline was 5.3/7 (where 1 = lowest quality and 7 = highest quality of guidance). ^aThe prescribing information for Naglazyme (galsulfase) contains warnings for anaphylaxis and severe allergic reactions, which have been reported in clinical studies [25, 26]. Medical support should be present during all treatments. If these reactions occur, ERT infusion should be immediately halted and treatment given